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Abstract
Objective—To examine dysregulation in biological measures associated with histories of abuse in
women and whether women with premenstrual dysphoric disorder (PMDD) differ in their
dysregulation.
Design—Twenty-five women meeting prospective criteria for PMDD and 42 non-PMDD controls
underwent structured interview to determine abuse histories and lifetime Axis I diagnoses, excluding
those with current Axis I disorders or using medications.
Major Outcome Measures—Plasma cortisol and norepinephrine (NE), heart rate (HR), blood
pressure (BP), and vascular resistance index (VRI) were assessed at rest and in response to mental
stress.
Results—A greater proportion of PMDD women had prior abuse compared with non-PMDD
women. Regardless of PMDD status, all abused women had lower plasma NE and higher HRs and
tended to have lower plasma cortisol at rest and during stress. Abused women also reported more
severe daily emotional and physical symptoms. Greater VRI and BP at rest and during stress were
seen only in PMDD women with abuse.
Conclusion—There is persistent dysregulation in stress-responsive systems in all abused women
that cannot be accounted for by current psychiatric illness or medications, and PMDD women may
be differentially more vulnerable to the impact of abuse on measures reflecting α-adrenergic receptor
function.
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Abuse rates for women in the United States are sobering. Population-based national surveys
have indicated that 13%–27% of women were sexually abused as children (Badgley et al.,
1984; Finkelhor, Hotaling, Lewis, & Smith, 1990; MacMillan et al., 1997). When adult sexual
abuse, battering, and other forms of physical abuse are included, more than one third of women
from the general population have had these experiences (Resnick, Kilpatric, Dansky, Saunders,
& Best, 1993). The public health significance of abuse in women is underscored by the well-
established links between histories of abuse and psychiatric (Kendler et al., 2000) as well as
medical illness (Felitti et al., 1998; Leserman et al., 1996; McCauley et al., 1997). Animal
models provide ample evidence that severe or repeated stress exposure early in life leads to
long-term changes in neurobiology, as reflected in alterations in stress response systems that
persist throughout life (Bremner & Vermetten, 2001). On the basis of preclinical as well as
clinical evidence, it has been hypothesized that such persistent alterations in neurobiological
systems known to be stress responsive may contribute to the development of psychiatric illness
in women with abuse histories (Bremner & Vermetten, 2001; Heim, Newport, Bonsall, Miller,
& Nemeroff, 2001).
The stress response system that has been most studied to date in relation to traumatic or abuse
histories in humans is the hypothalamic–pituitary–adrenal (HPA) axis. The results of these
studies have been mixed with most (Heim et al., 2001; Newport, Heim, Bonsall, Miller, &
Nemeroff, 2004; Resnick, Yehuda, Pitman, & Foy, 1995; Stein, Yehuda, Koverola, & Hanna,
1997; Yehuda, Giller, Levengood, Southwick, & Siever, 1995), although not all (Heim et al.,
2000b; Young, Tolman, Witkowski, & Kaplan, 2004) finding evidence for lower cortisol
concentrations or blunted cortisol reactivity to challenge in individuals with trauma or abuse
histories. Fewer studies have examined noradrenergic function related to trauma or abuse in
humans. However, taken together, the results of those studies have suggested increased
noradrenergic activity in adults with prior traumatic stress (for a review, see Bremner &
Vermetten, 2001).
It is important to note that many of the studies investigating HPA or noradrenergic function in
women with prior abuse histories have been met with interpretive issues in examining the
impact of prior abuse on persistent neuroendocrine dysregulation, as the majority of these
studies included women with current psychiatric illness or who were taking psychotropic
agents (Heim et al., 2000b; Lemieux & Coe, 1995; Metzger et al., 1999; Orr et al., 1998; Stein
et al., 1997). Indeed, the important interactive effects of current depression and histories of
abuse on HPA axis function have been documented (Heim et al., 2000b; Kaufman et al.,
1997). However, a report by Heim et al. (2001) provided the strongest evidence to date that
histories of abuse have persistent effects on HPA axis function in women in the absence of
current depression or medication use. In that study, adult women with a history of childhood
sexual or physical abuse and no current major depression or medication use displayed greater
adrenocorticotropic hormone (ACTH) concentrations following corticotrophin-releasing
hormone stimulation and blunted plasma cortisol concentrations following ACTH stimulation
relative to women with childhood abuse plus current depression, women with current
depression but no abuse, and healthy controls. These results suggested that there may be
sensitization of the anterior pituitary and counterregulatory adaptation of the adrenal cortex in
abused women even in the absence of current depression (Heim et al., 2001).
Research from our laboratory has also obtained evidence for persistent dysregulation in stress
response systems associated with prior sexual or physical abuse in the absence of current Axis
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I disorders or medication use in women with premenstrual dysphoric disorder (PMDD).
Relative to the general population, PMDD women have significantly greater rates of lifetime
sexual and physical abuse (rates > 60%; Girdler et al., 2003; Golding & Taylor, 1996; Golding,
Taylor, Menard, & King, 2000; Paddison et al., 1990). Results from our prior studies have
suggested that these women may be more vulnerable to the effects of prior abuse in measures
reflecting noradrenergic function as only PMDD women with abuse histories displayed greater
resting and stress-induced heart rates (HRs) and systolic blood pressure (SBP; Bunevicius,
Hinderliter, Leserman, Pedersen, & Girdler, 2005), as well as increased β-adrenergic receptor
responsivity coupled with lower circulating plasma norepinephrine (NE; Girdler et al., 2003)
relative to PMDD women with no abuse history—effects not seen in nonabused, non-PMDD
women. In contrast, non-PMDD women with abuse histories had lower plasma cortisol
concentrations at rest and in response to stress relative to nonabused, non-PMDD women
(Girdler et al., 2003).
Although these earlier studies provided initial evidence that the biological correlates of abuse
persist even in the absence of current psychiatric illness and that they may differ for PMDD
women, they were limited by our failure to control for differences in histories of psychiatric
illness between abused PMDD and abused non-PMDD women, particularly histories of
depression. It is well established that histories of depression are more common in abused
women (Kendler et al., 2000) and may be more common in those with PMDD (Pearlstein et
al., 1990). Our own work (Klatzkin, Morrow, Light, Pedersen, & Girdler, 2005; Pedersen et
al., 1993) and that of Young, Aggen, Prescott, and Kendler (2000) have demonstrated that
dysregulation in stress-responsive systems persists even in euthymic women who have a history
of depression. For example, Young et al. found persistent elevation in salivary cortisol in
women with a history of but no current major depressive disorder relative to never-depressed
women. Similarly, a study on thyroid and adrenal measures during pregnancy and the
puerperium found significantly elevated plasma cortisol in women during the puerperium who
had prior depression relative to women with negative psychiatric histories (Pedersen et al.,
1993). Most recently, we documented that women with no current depression but with prior
major depressive disorder, minor depression, or adjustment disorder with depressed mood
show blunted allopregnanolone responses to mental stress relative to never-depressed women
(Klatzkin et al., 2005). Thus, it is possible that the results of Heim et al. (2001) and our own
prior studies (Bunevicius et al., 2005; Girdler et al., 2003) documenting persistent alterations
in stress-responsive measures in PMDD women with histories of abuse but no current
psychopathology reflect the influence of their greater rates of prior depressive episodes and
not differential effects of abuse per se.
Consequently, the purpose of this study was twofold. First, it was designed to replicate our
earlier work showing a differential impact of abuse on noradrenergic function in PMDD
women, as this would implicate noradrenergic mechanisms in the pathophysiology of PMDD.
Thus, we recruited an entirely new sample of PMDD and non-PMDD controls for the present
study, used structured interview to assess abuse histories, and used psychophysiological
techniques to measure indices of noradrenergic and HPA axis function. Second, we sought to
extend prior work suggesting persistence of dysregulation in both HPA axis and noradrenergic
systems in women with abuse histories by carefully assessing and matching groups for histories
of depressive episodes. A tertiary goal was to examine the association of abuse histories with
daily symptom ratings in both the follicular and luteal phases of the menstrual cycle.
Method
Subjects
Twenty-five women prospectively diagnosed with PMDD and 42 non-PMDD controls
responded to newspaper, radio, or posted advertisements and met all inclusionary–exclusionary
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criteria (see below). To ensure relatively equal proportions of prior depression in PMDD and
non-PMDD groups, advertisements targeting women with histories of depression were also
used. All subjects were in good health, and none were taking any prescription medication,
including oral contraceptives or psychotropic agents. The protocol was approved by the
University of North Carolina at Chapel Hill Committee on Protection of the Rights of Human
Subjects. Subjects provided written informed consent prior to participation, and each received
$250 compensation.
Procedures
Assessment of PMDD—The Prospective Record of the Impact and Severity of Menstrual
Symptoms calendar (Reid, 1985) was used to classify both PMDD women and non-PMDD
controls. In addition to symptom severity ratings, the Prospective Record of the Impact and
Severity of Menstrual Symptoms calendar also incorporates measures of life style impact, life
events, and the use of medications. Calendars were completed daily for 2–3 menstrual cycles.
Criteria for PMDD were based on those of the Diagnostic and Statistical Manual of Mental
Disorders (4th ed., or DSM–IV; American Psychiatric Association, 1994), which include (a)
rating of symptoms as moderate or severe (as opposed to mild) premenstrually, (b) moderate
to severe symptoms on at least 3 of the 6 premenstrual days, (c) a total of five or more symptoms
premenstrually, (d) at least one moderate to severe emotional symptom, (e) evidence that
symptoms affected function, (f) a symptom-free period in the follicular phase, and (g) Criteria
1–6 met on two consecutive menstrual cycles. Non-PMDD control women met the following
criteria: (a) not completely asymptomatic during the premenstrual week (i.e., to exclude women
biased to nonreporting), (b) having only mild emotional symptoms premenstrually, (c)
moderate physical symptoms on fewer than 3 days premenstrually, and (d) no evidence that
symptoms affected normal functioning.
Structured Clinical Interviews
Psychiatric histories: Structured clinical interviews (Structured Clinical Interview for DSM–
III–R; Spitzer, Williams, Gibbon, & First, 1992) based on DSM–IV criteria for Axis I disorders
were conducted. All diagnoses were based on a consensus diagnostic session with a psychiatrist
(Cort A. Pedersen). For present purposes, women classified with lifetime depression met
criteria for either lifetime major depressive disorder (11 non-PMDD, 13 PMDD), minor
depressive disorder (4 non-PMDD, 1 PMDD), or adjustment disorder with depressed mood (2
non-PMDD, 1 PMDD). Because lifetime histories of depressive episodes are prevalent in
women (Weissman & Olfson, 1995), 7 months in full remission was required for lifetime
depression. For other Axis I disorders, 3 years in full remission was required.
Sexual and physical abuse histories: After administration of the Structured Clinical Interview
for DSM–III–R, subjects were asked about sexual and physical abuse histories using a modified
version of a validated interview (Leserman et al., 1996). This interview correlates highly with
many indicators of poor health (Leserman, Li, Drossman, & Hu, 1998), indicating its predictive
validity, and the reliability of this interview compared with questionnaire measures of abuse
is established (Leserman, Drossman, & Li, 1995). Sexual abuse included the following
experiences in which force or threat of harm was used: (a) sexual touching with hands, mouth,
or objects; (b) making the subject touch the perpetrator with hands, mouth, or objects; and (c)
making the subject have vaginal or anal intercourse. To meet criteria for sexual abuse incidents
as an adult or adolescent, there had to be clear threat of harm or force (pressure for sexual
activity was not sufficient). To meet criteria as a child (younger than 14 years of age), the threat
of force did not have to be as clearly established if it was implied by the age differential between
perpetrator and victim. Physical abuse was defined as incidents separate from sexual abuse
that included (a) life threat (being physically attacked with or without a weapon, with the intent
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to kill or seriously injure) and (b) other physical abuse (beat, hit or kicked, bit or burned) by
another person—incidents outside the range of normal spanking or kids fighting.
For analytic purposes, we combined sexual and physical abuse experiences in the present study
as previous research has shown that both types of abuse are related to numerous indicators of
poor health status (Felitti et al., 1998; Leserman et al., 1996). Women were included with
childhood (younger than 14 years of age), adolescent (14–19 years of age), or adult (older than
20 years of age) abuse experiences. PMDD and non-PMDD women did not differ in number
with first abuse experience in childhood (9 vs. 6, respectively), in adolescence (1 vs. 3), or in
adulthood (2 vs. 3). Ten women with abuse histories had experienced both sexual and physical
abuse (7 PMDD and 3 non-PMDD), 4 had prior sexual abuse only (1 PMDD and 3 non-PMDD),
and 10 had prior physical abuse only (4 PMDD and 6 non-PMDD).
Physiological Recording Procedures—Blood pressure (BP) was recorded
noninvasively using the auscultatory technique. An automated blood pressure monitor
(Suntech, 4240 Blood Pressure Monitor) was used to measure blood pressure. SBP
corresponded to the onset of K-sounds, and diastolic blood pressure (DBP) corresponded to
the disappearance of K-sounds. Manual stethoscopic readings were taken initially using a
sphygmomanometer to ensure correct placement of the microphone.
Impedance cardiography was used to permit noninvasive monitoring of cardiac performance
(Sherwood et al., 1990), including stroke volume, HR, and preejection period. A custom-
designed impedance cardiograph (HIC-100, Bioimpedance Technology, Inc., Model 100,
Chapel Hill, North Carolina) was used in conjunction with a tetrapolar band electrode
configuration to record impedance dZ/dt and Zo signals. Impedance and electrocardiogram
signals were processed online by specialized computer software (BIT, Chapel Hill, North
Carolina) with subsequent manual editing to improve accuracy. For each minute of interest, a
30-s continuous sample of waveforms (obtained concurrently with BP) was processed to
generate an ensemble-averaged cardiac cycle, from which stroke volume was determined by
means of the Kubicek, Krnegis, Patterson, Witsoe, and Mattson (1966) equation and HR was
determined by the mean interbeat interval. Cardiac output and total peripheral resistance for
these same minutes were then calculated using standard formulas (Sherwood et al., 1990). To
control for group differences in body mass index (see the Results section), stroke volume,
cardiac output, and total peripheral resistance were adjusted for individual differences in body
size by using body surface area to derive stroke volume index, cardiac index (CI) and vascular
resistance index (VRI).
Experimental Procedures—Each subject was tested twice, once during her early follicular
phase (Days 2–6) and once 8–12 days after home urine testing (Clearplan Easy®) revealed the
luteinizing hormone surge. All cycles were later confirmed to be ovulatory using serum
progesterone. Cycle phase at first testing was counterbalanced within groups. Before testing,
subjects were instructed to refrain from all over-the-counter medications for 24 hr, caffeine for
8 hr, and nicotine for 1 hr. All laboratory test sessions began between 0730 and 0900.
Immediately on arriving at the laboratory, subjects were instrumented for cardiovascular
monitoring. Next, an IV line was established in an arm vein, and once in place, a curtain was
drawn that prevented the subject from viewing the IV. A minimum of 15 min elapsed between
establishing the IV and beginning baseline rest. Subjects were then exposed to the following
conditions.
Baseline rest: Subjects rested alone and quietly for 10 min. Blood pressure and impedance-
derived measures were taken at Minutes 1, 3, 5, 7, and 10 and averaged. Blood was sampled
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at Minute 10 for baseline NE and cortisol and for estradiol and progesterone concentrations to
verify cycle phase.
Trier Social Stress Test (TSST; Kirschbaum, Pirke, & Hellhammer, 1993): We used a
modified version of the TSST (modified to include serial addition as opposed to serial
subtraction). The TSST is a stress test that reliably induces large and consistent HPA and
cardiovascular responses (Kirschbaum, Klauer, Filip, & Hellhammer, 1995; Kirschbaum et al.,
1993; Kirschbaum, Prussner, et al., 1995). The TSST involves four components:
1. Pretask instructions: During pretask instructions, subjects were introduced to the
“selection committee” who would later listen to their job talk. Subjects were also
given the instructions for the mental arithmetic task. The duration of the instruction
period averaged 5 min.
2. Speech preparation period: During this period, subjects were left alone for 5 min to
prepare their talk.
3. Job speech: Immediately following the preparation period, the selection committee
returned to the testing room and asked the subject to deliver his or her talk describing
to the committee why he or she would be the perfect applicant for the position. If the
subject finished before 5 min, the committee responded in a standardized way with
prepared questions to ensure that the subject spoke for the entire period. Talks were
tape recorded, and subjects had the opportunity to earn up to $10, based on the
committee’s ratings of their speech performance. Cardiovascular measures were taken
at Minutes 1, 3, and 5 and averaged. Blood was sampled for plasma NE at the end of
Minute 2.
4. Paced Auditory Serial Addition Test (PASAT; Gronwall, 1977): The PASAT involves
the tape-recorded presentation of numbers from 1 to 9 and lasted 8.5 min. Subjects
added each number presented on the tape to the immediately preceding number and
stated the answer aloud. There were four series of numbers, with progressively shorter
interdigit intervals. The experimenter remained in the room to monitor performance.
Subjects had the opportunity to earn up to $10, based on the total number of correct
additions. Cardiovascular measures were taken once each of the four series and
averaged. Blood was sampled for plasma NE at the end of minute 2.
Stress recovery: Subjects rested quietly alone for 10 min. Blood was sampled at the end of
this recovery period to capture the delayed plasma cortisol response to the TSST (Kirschbaum,
Klauer, et al., 1995; Kirschbaum, Prussner, et al., 1995).
Hormone and Neuroendocrine Assays—Blood for cortisol was collected into
ethylenediamine tetraacetic acid–treated tubes, and blood for NE was collected into
heparintreated tubes. Tubes were placed immediately on ice and cold centrifuged to separate
plasma within a few minutes after collection. Plasma was pipetted into aliquot tubes, rapidly
frozen, and maintained at −80°C until assayed. Plasma levels of cortisol were determined by
radioimmunoassay using commercial kits from ICN Pharmaceuticals (Hampshire, United
Kingdom). The sensitivity of the assay is excellent at 0.07 µg/dL. The specificity of the radio-
immunoassay for cortisol is high, showing only 0.05%–2.2% cross-reactivity with most
similarly structured compounds. Plasma levels of NE were determined using the high
performance liquid chromatography technique. The lower limit of quantification with this
system is 25 pg/ml, and the intra- and interday coefficients of variation are less than 10%.
Serum levels of progesterone were determined with radioimmunoassay kits from ICN
Pharmaceuticals, Inc. The specificity of the antiserum for progesterone is very high, showing
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only 0.01%–2.5% cross-reactivity with other steroid compounds. Progesterone levels less than
3 ng/ml in the luteal phase of the cycle were considered reflective of an anovulatory cycle.
Data Reduction and Analyses—Differences in age and body mass index were analyzed
using a 2 (group: PMDD vs. non-PMDD) × 2 (abuse: yes vs. no) analysis of variance
(ANOVA), and abuse-related differences in the proportion of women meeting criteria for
lifetime Axis I disorders was analyzed using chi-square analyses.
We examined the influence of histories of abuse and the menstrual cycle on cardiovascular and
neuroendocrine measures, using 2 (group) × 2 (abuse) × 2 (phase) × 3 (condition: baseline,
speech, math) repeated measures ANOVAs with phase and condition as the repeated factors.
Where significant interactions emerged, subsequent simple effects analyses were conducted
to examine the source of the effect. Finally, the influence of prior abuse on mean daily symptom
ratings was examined. To reduce Type I error rates, only five symptoms were examined,
representing common and distressing premenstrual symptoms: irritability, anger, depression,
headache, and fatigue. Mean follicular and luteal phase symptom scores were based on the
average, across two menstrual cycles, of the severity ratings during days 4–9 of the follicular
phase and the severity ratings during the 6 days preceding menses (luteal phase). A 2 (group)
× 2 (abuse) × 5 (symptom) × 2 (phase) repeated measures ANOVA was used, with symptom
and phase as the repeated factors.
Results
Abuse Histories
A greater proportion of PMDD women relative to non-PMDD women had histories of both
physical abuse (11 of 25 vs. 9 of 42), χ2(1) = 3.8, p = .05, and sexual abuse (8 of 25 vs. 6 of
42), χ2(1) = 3.0, p = .08. Thus, there was a tendency for a greater proportion of PMDD women
to be classified with prior abuse (either sexual or physical) relative to non-PMDD women (12
of 25 vs. 12 of 42), χ2(1) = 2.6, p = .10.
Demographic Factors and Psychiatric Histories
Table 1 summarizes selected demographic and psychiatric history variables. Although groups
did not differ in age, PMDD women with abuse histories had greater body mass index than did
nonabused PMDD women, Group × Abuse F(3, 66) = 3.0, p < .05. Thus, stroke volume, cardiac
output, and total peripheral resistance were adjusted for differences in body size to yield stroke
volume index, CI, and VRI.
As expected, all women with histories of abuse (n = 24) were more likely to meet criteria for
histories of depression than were nonabused women (17 of 24 vs. 16 of 43), χ2(1) = 7.0, p < .
01. However, the abused PMDD and abused non-PMDD groups did not differ in the proportion
with prior depression (67% and 75%, respectively), nor did the nonabused groups (46% and
33%). In the PMDD sample only, 33% of the PMDD women with abuse histories also had
histories of posttraumatic stress disorder (PTSD) compared with 0% of the nonabused PMDD
women, χ2(1) = 5.2, p < .05, whereas abuse was not associated with different rates of prior
PTSD in non-PMDD women.
Cardiovascular and Neuroendocrine Levels at Rest and During Stress
Effects of Abuse Histories—All women with histories of abuse, regardless of PMDD
diagnosis or menstrual cycle phase, exhibited significantly lower plasma NE concentrations at
rest and during mental stressors relative to nonabused women, main effect of abuse F(1, 63)
= 5.3, p < .05 (see Figure 1). All women with histories of abuse also had significantly greater
HR levels at rest and during stressors in both cycle phases, main effect of abuse F(1, 63) = 4.0,
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p < .05 (see Figure 2). For cortisol, an Abuse × Phase trend was obtained, F(1, 63) = 3.1, p < .
10 (see Table 2). Subsequent simple effects analyses conducted separately in the two cycle
phases revealed that only in the follicular phase did abused women tend to have lower plasma
cortisol at rest and poststress relative to nonabused women, F(1, 63) = 2.8, p < .10, whereas
no abuse-related differences existed in the luteal phase.
In addition to the effects of abuse history on HR, plasma NE, and cortisol that were present in
all women, we also obtained evidence for a differential effect of abuse in PMDD women for
measures of blood pressure and vascular resistance. As illustrated in Figure 3, only for the
PMDD women was prior abuse associated with elevated VRI measures at rest and during stress
in both cycle phases, Group × Abuse F(1, 63) = 3.9, p = .05. Similarly, for blood pressure only
for PMDD women was prior abuse associated with significantly elevated SBP, Group × Abuse
F(1, 63) = 6.7, p < .05 (see Table 2) and DBP, Group × Abuse F(1, 63) = 5.7, p × .05, in both
cycle phases (see Figure 4).
There were no group or abuse-related effects for stroke volume index or CI (Table 2). With
the exception of cortisol, for each dependent measure significant main effects of condition
were obtained, Fs(3, 61) = 3.1–136.7, ps < .05, reflecting the significant change from baseline
to stressors. There were no significant Abuse × Condition interactions, indicating that all group
differences summarized above were evident under both baseline and stressor conditions.
Failure to observe a significant condition effect for cortisol (i.e., stress effect) was likely due
to the fact that we tested all subjects in the morning, when diurnal effects on cortisol are greatest
(Kudielka & Kirschbaum, 2005).
Effects of the Menstrual Cycle—Although, with the exception of cortisol, the overall
abuse-related effects described above were evident in both menstrual cycle phases, this is not
to say that the menstrual cycle did not influence cardiovascular and neuroendocrine measures.
For all women, regardless of abuse or PMDD status, the luteal phase of the menstrual cycle
was associated with significantly greater plasma NE concentrations, F(1, 60) = 13.2, p < .001
(see Figure 1); greater HR and CI levels, Fs(1, 60) = 6.4 and 6.1, ps < .05, respectively (see
Table 2 and Figure 2); and lower VRI levels, F(1, 60) = 6.1, p < .05 (see Figure 3), than the
follicular phase. There were no cycle-related effects for SBP, DBP, or stroke volume index.
Influence of Abuse on Daily Symptom Ratings—Mean daily severity ratings as a
function of PMDD and abuse status are presented in Table 3. As expected, all PMDD women,
regardless of abuse history, had greater symptom severity ratings, especially in the luteal phase,
Group × PhaseF(1, 62) = 39.3, p < .0001. An overall effect of abuse was also obtained,
reflecting the generally greater symptom levels in abused versus nonabused women, F(1, 62)
= 5.4, p < .05, collapsed across cycle phase. This was qualified, however, by a Phase × Symptom
× Abuse × Group interaction, F(4, 59) = 3.5, p < .05, which was explored by examination of
all least-squares means comparisons. These comparisons indicated that in the follicular phase,
PMDD women with abuse had greater symptom severity for anger, irritability, depression, and
headache than did nonabused PMDD women (all ps < .05), whereas abused, non-PMDD
women had greater depression and fatigue ratings than did nonabused, non-PMDD women
(ps < .05). In the luteal phase, the only significant effects to emerge regarding abuse histories
were for the non-PMDD women, as abused, non-PMDD women had greater irritability (p < .
05) than did nonabused, non-PMDD women.
Discussion
The results of our study add to a divergent yet growing body of knowledge indicating that early
life exposure to abuse leads to persistent and long-term dysregulation in stress-responsive
systems. Moreover, our study is among the first to demonstrate persistent cardiovascular and
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neuroendocrine dysregulation in women with histories of abuse who are not currently suffering
from psychiatric illness or using psychotropic medications. Our study is also among the first
to examine noradrenergic mechanisms in adult survivors of abuse. We found that irrespective
of PMDD diagnosis or menstrual cycle phase, women with histories of abuse had lower
circulating plasma NE concentrations at rest and during stress. Although most clinical studies
have reported increased noradrenergic activity in adults with prior traumatic stress, as reflected
in circulating NE concentrations or increased responsiveness of the sympathadrenal system
(see Bremner, Krystal, Southwick, and Charney, 1996, and Bremner & Vermetten, 2001, for
reviews), this finding may likely reflect the impact of current comorbid PTSD that was present
in many of these studies. Indeed, Lemieux and Coe (1995) found that only women with both
abuse histories and current PTSD had greater urinary NE concentrations relative to nonabused
controls, similar to the finding of Young and Breslau (2004) that individuals with lifetime
PTSD had higher urinary catecholamine concentrations than trauma-exposed/never-PTSD and
nonexposed groups. Even more relevant to our results is the evidence documented by these
same investigators (Young & Breslau, 2004) indicating an impact of trauma exposure, per se,
on urinary catecholamines, as the trauma-exposed/never-PTSD group had significantly lower
concentrations than the nonexposed group—a pattern remarkably similar to our finding for
reduced plasma NE in abused women free of current PTSD and depression. Young and Breslau
suggested that reduced catecholamine concentrations in individuals with histories of traumatic
stress may reflect a long-term adaptation to trauma exposure.
It should be noted that our findings of reduced plasma NE coupled with greater HR at rest and
during stressors in abused women may at first seem paradoxical, as catecholamines, including
NE, act to stimulate HR increases via stimulation of β-adrenergic receptors. However, this
finding is, in fact, consistent both with pharmacological theory and with the findings from our
earlier study showing lower circulating plasma NE coupled with increased β-adrenergic
receptor responsivity in PMDD women with histories of abuse (Girdler et al., 2003). Increased
β-adrenoceptor responsivity would be consistent with pharmacological up-regulation of the
receptors in response to diminished agonist (i.e., diminished NE) and would mediate, at least
in part, the increased HRs that we documented in all abused women in the present study. This
hypothesis is speculative, however, as no assessment of β-adrenoceptor responsivity was made
in this study. Nevertheless, we did document alterations in peripheral β-adrenoceptor function
associated with abuse in our prior study (Girdler et al., 2003), and such alterations may have
pathophysiological relevance with respect to the mood disturbance seen in abuse. Increased
β-adrenoceptor density has been documented in clinical depression (Leonard, 1997) and is
associated with premenstrual symptom severity in PMDD women (Gurguis et al., 1998).
Additional studies assessing β-adrenergic receptor function and relationship to symptoms and
mood in abused women are needed to address the pathophysiological role of β-adrenergic
receptors in the psychiatric comorbidity associated with abuse.
Our study also investigated HPA axis function, as reflected in plasma cortisol concentrations.
Although only a trend, our finding of lower cortisol in abused women, at least in the follicular
phase, is consistent with many studies on HPA axis function in abused women, reporting lower
cortisol concentrations or blunted response to challenge (Heim et al., 2001; Newport et al.,
2004; Resnick et al., 1995; Stein et al., 1997). However, our results suggest that the
hypocortisolemia noted in so many studies of traumatized individuals may represent a
persistent effect of the exposure to traumatic stress and is not necessarily a result of current
comorbid clinical depression or PTSD or the use of psychotropic medications. Indeed, our
findings are consistent with the study by Heim et al. showing blunted plasma cortisol to ACTH
challenge in adult women with childhood abuse who were free of current depression and
medication use and consistent with the study of Resnick et al. showing that women with a
previous history of rape had lower cortisol responses to a subsequent rape than women who
were raped but had no previous rape history. These findings, taken together, are in keeping
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with the emerging evidence that chronic or severe stress exposure can result in persistent
alterations in neurobiological systems that are stress responsive (Heim et al., 2001) and that
this can be manifest in hyporesponsiveness of the system to subsequent stressors, as has been
documented in animal models of early life stress and HPA axis function (Coplan et al., 1996;
Ladd, Owens, & Nemeroff, 1996). Hypocortisolemia may have special clinical relevance as
recent evidence has indicated that blunted HPA axis function is associated with a number of
stress-related bodily disorders (Heim, Ehlert, & Hellhammer, 2000).
It has been suggested that a genetic vulnerability coupled with early stress in a critical and
plastic period of development may result in persistent alterations in neurobiological systems
that are known to be stress responsive, resulting in dysregulation in stress responsiveness to
even mild stressors in adulthood and forming the basis for the development of mood disorders
(Heim et al., 2001). Despite the fact that none of the women in the present study met diagnostic
criteria for a current mood disorder, our finding that all women with histories of abuse, who
displayed persistent dysregulation in measures reflecting both the HPA axis as well as the
sympathetic nervous system, had more severe daily emotional and physical symptom ratings
than did nonabused women suggests a persistence of mood disturbance associated with abuse
history even in the absence of meeting current clinical criteria. It is interesting to note, however,
that greater symptom levels in abused versus nonabused PMDD women were evident only in
their follicular phase. Although the reason for this remains unknown, we hypothesize that the
magnitude of symptom severity evident in the luteal phase for all PMDD women, a defining
feature of their disorder, may override the more subtle influence of abuse histories on symptom
severity.
The persistent dysregulation in neuroendocrine and HR levels seen later in life in women with
abuse histories is a remarkable feature of our findings. Although we did include women whose
first abuse experience occurred as an adult (age range = 20–24 years), 80% of our study sample
consisted of women who had experienced childhood or adolescent abuse, with the majority
experiencing abuse in childhood (60%). Thus, many years, if not decades, had elapsed since
some of the women in the present study had experienced abuse. This is consistent with the
work of Wang and Mason (1999) showing persistent disturbance in HPA axis function in male
combat veterans 40–50 years following combat. This is also consistent with the observation
of altered ACTH and cortisol responses to challenge in adult women with histories of childhood
sexual abuse (Heim et al., 2001; Heim, Newport, et al., 2000). Thus, it is possible that
dysregulation of neuroendocrine factors in women with abuse histories represents an adaptation
gone awry if the stress axes continue to prepare the individual for a severe stressor that no
longer exists but somehow remains encoded in the brain (Prange, 1999).
Finally, although we found that all women with abuse histories share a common dysregulation
in NE and HR, and possibly in cortisol, we also obtained evidence, even after matching abused
groups for depressive histories, that the biological correlates of abuse may differ for PMDD
women. Specifically, consistent with results from our prior studies indicating that PMDD
women may be more vulnerable to the influence of abuse histories on measures reflecting
adrenergic physiology (Bunevicius et al., 2005; Girdler et al., 2003), only the PMDD women
with abuse had greater VRI levels and greater BP levels at rest and during stress—effects not
seen in the non-PMDD women. Because abused PMDD and abused non-PMDD women did
not differ in HR or CI levels, the greater BP in abused PMDD women was likely mediated by
their enhanced vascular tone. Studies using adrenergic receptor blockers in humans have shown
that individual differences in total vascular resistance at rest and during mental stress are
mediated, at least in part, by vascular α-adrenergic receptors (Girdler, Hinderliter, & Light,
1993).
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We have recently reported the results from a randomized, placebo-controlled, cross-over study
that used a long-term clonidine challenge test (centrally acting, α2-receptor agonist) to
investigate α2-adrenergic receptor mechanisms as a function of sexual abuse histories in 12
PMDD women (Bunevicius et al., 2005). We found that clonidine was associated with
significantly greater reductions in resting and stress-induced BP and HR in the abused PMDD
women compared with nonabused PMDD women, suggesting that abuse experiences may
modify presynaptic α2-adrenoceptor function in PMDD. This interpretation is limited,
however, by the relatively small sample size and by the lack of inclusion of non-PMDD
controls. However, the potential patho-physiological role for α-adrenoceptors in PMDD
women with abuse histories comes from reports showing altered α-adrenoceptor function in
other psychiatric disorders, including mood disorders (Mokrani, Duval, Diep, Bailey, &
Macher, 2000; Siever et al., 1982), PTSD (Morris, Hopwood, Maguire, Norman, & Schweitzer,
2004), and menstrual migraine (Facchinetti et al., 1989). More direct evidence comes from
studies relating α2-adrenoceptor function directly to symptoms in PMDD women. For
example, Gurguis et al. (1998) found positive correlations between luteal phase platelet α2-
receptor density and premenstrual symptoms in PMDD women, and Halbreich, Piletz, Carson,
Halaris, and Rojansky (1993) found increased α2-receptor binding in women with dysphoric
PMS compared with symptom-free women and that binding was highly correlated with
symptom severity (Halbreich et al., 1993). Although neither of these studies examined abuse
histories, given the greater prevalence rates for abuse in PMDD (Girdler et al., 2003; Golding
et al., 2000; Paddison et al., 1990), the possibility exists that their findings linking α2-
adrenoceptor function to symptoms may reflect differential dys-regulation of α2-receptors in
PMDD women with histories of abuse.
In conclusion, the results of our study indicate that histories of sexual and physical abuse are
associated with persistent alterations in stress-responsive systems in women, even in the
absence of current psychiatric illness or medication use. Our results also suggest, however,
that PMDD women may be more vulnerable to the effects of abuse experiences on α-adrenergic
receptor function as only PMDD women with abuse exhibited greater vascular tone and blood
pressure levels relative to nonabused PMDD women. As α-adrenoceptor function has been
linked to mood disorders (Mokrani et al., 2000; Siever et al., 1982), PTSD (Morris et al.,
2004) and to premenstrual symptom severity in PMDD women (Gurguis et al., 1998; Halbreich
et al., 1993), future studies examining α-adrenoceptor function separately in PMDD and non-
PMDD women as a function of abuse histories are clearly indicated and may have important
treatment implications for PMDD—a heterogeneous disorder with respect to
pathophysiological mechanisms (Halbreich, 1993), and one associated with a 50%
nonresponse rate to selective serotonin reuptake inhibitors (e.g., Pearlstein et al., 2000; Steiner
et al., 1995).
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Plasma norepinephrine (NE; pg/ml) at baseline rest and during stressors in PMDD (top panel)
and non-PMDD women (bottom panel) as a function of abuse histories and menstrual cycle
phase. PMDD = premenstrual dysphoric disorder. Error bars represent the standard error of
the mean.
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Heart rate (HR, in beats per minute [bpm]) at baseline rest and during stressors in PMDD
women (top panel) and non-PMDD women (bottom panel) as a function of abuse history and
menstrual cycle phase. PMDD = premenstrual dysphoric disorder. Error bars represent the
standard error of the mean.
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Vascular resistance index (VRI; [dyne – sec × cm−5] × BSA) at baseline rest and during
stressors in PMDD women (top panel) and non-PMDD women (bottom panel) as a function
of abuse history and menstrual cycle phase. BSA = body surface area; PMDD = premenstrual
dysphoric disorder. Error bars represent the standard error of the mean.
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Diastolic blood pressure (DBP; mmHg) at baseline rest and during stressors in PMDD women
(top panel) and non-PMDD women (bottom panel) as a function of abuse history and menstrual
cycle phase. Error bars represent the standard error of the mean.
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Table 1












  M 35 31 34 35
  SD 1.9 1.8 1.9 1.2
BMIa
  M 27.3 21.9 25.0 24.7
  SD 1.3 1.2 1.3 0.8
Psychiatric history
  Depressionb
    n 8 6 9 10
    % 67 46 75 33
  PTSDa
    n 4 0 1 0
    % 33 8
  Anxiety
    n 2 3 3 2
    % 17 23 25 7
  Substance
    n 2 0 3 3
    % 17 25 10
  Eating disorders
    n 2 2 1 1
    % 17 15 8 3
Note. PMDD = premenstrual dysphoric disorder; BMI = body mass index; PTSD = posttraumatic stress disorder.
a
PMDD with abuse > PMDD no abuse, p < .05.
b
Abuse > no abuse, p < .01.
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